Jump to the main content block
  1. Home
  2. TEAM
  3. Division of Medical Oncology

Wen-Pin SU

Research NCKU

Highest educational qualification

Ph.D., Institute of Clinical Medicine, National Cheng Kung University

 

Experience & Position

2024.8~ present, Distinguished Professor, Institute of Clinical Medicine, NCKU.
2023.8~ present, Director, Institute of Clinical Medicine, NCKU.
2023.8~ present, Director, Clinical Medicine Research Center, NCKUH.
2023.8~ present, Director, the International Medical Program in Interneuroscience, NCKU.
2021.8~ present, Professor, Institute of Clinical Medicine, NCKU.
2021.8~ present, Joint Appointment Professor, Departments of Oncology, Internal Medicine and Urology, School of Medicine, NCKU.
2020.10~ Present, Attending Physician, Department of Oncology, NCKUH.
2020.8~2023.7, Deputy Director, Cancer Center, NCKUH.
2017.8~2021.7, Associate Professor, Institute of Clinical Medicine, NCKU.
2017.8~2021.7, Joint Appointment Associate Professor, Departments of Oncology, Internal Medicine and Urology, School of Medicine, NCKU.
2015.8~2017.7, Assistant Professor, Institute of Clinical Medicine, NCKU.
2013.2~2017.7, Clinical Assistant Professor, School of Medicine, NCKU.
2005.7~2020.9, Attending Physician, Department of Internal Medicine, NCKUH.
1999.7~2005.6, Residency, Departments of Internal Medicine and Oncology, National Taiwan University Hospital.

 

Publications

  1. Cheng TY, Chang LC (Dr. Su’s postdoctal researcher), Yang LX, Wu SS, Chin YC, Chen YJ, Chia ZC, Su WP*, Huang CC*. Bioactive Light-Responsive Au Nanohybrids for Reactive Oxygen Species-Driven Macrophage Reprogramming. ACS Applied Materials & Interfaces. 2025 Oct 1;17(39):54453-54465. (Corresponding author) (IF:8.2)
  2. Chin YC, Chen YT, Chiu YC, Wu SR, Chang LC, Yang LX, Liu HS, Wu GC, Yu CC, Dong DC, Chiang IT, Liu YC, Su WP, Hsu FT*, Huang CC*. Galactosylated iron oxide nanoplatforms for targeted imaging and ferroptosis-enhanced glioblastoma therapy via immune modulation. Materials Horizons. 2025 Aug 14; 12(22):9697-9714. (Co-author) (IF:10.7)
  3. Gupta T (Dr. Su’s Ph.D.student), Wu SR, Chang LC, Lin FC, Shan YS, Yeh CS, Su WP*(only corresponding author). Radiocleavable rare-earth nanoactivators targeting over-expressed folate receptors induce mitochondrial dysfunction and remodel immune suppressive microenvironment in pancreatic cancer. Journal of Nanobiotechnology. 2025 Aug 12;23(1):562. (Corresponding author) (IF:12.6)
  4. Chen YC, Chang LC, Liu TL, Chang MC, Liu YF, Change PY, Manoharan D, Wang WJ, Chen JS, Wang HC, Chiu WT*, Li WP*, Sheu HS*, Su WP*, Yeh CS*. Redox disruption using electroactive liposome coated gold nanoparticles for cancer therapy. Nature Communications. 2025 Apr 5;16(1):3253. (Corresponding author) (IF: 15.7) —2025年未來科技獎 / 國家新創獎-學研新創
  5. Yeh CF, Chen CC, Lai CC, Liu JW, Tang HJ*, Su WP*. Synergistic effect of repurposed mitomycin C in combination with antibiotics against  Aeromonas  infection: In vitro and in vivo studies. Journal of Microbiology Immunology and Infection. 2025; 58(2):189-197. (Corresponding author) (IF: 3.7)
  6. Giannatempo P*, Machiels JP, Sassa N, Arranz JA, Fujii Y, Su WP, et al. Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials. Clinical Genitourinary Cancer. 2025 Apr;23(2):102273. (Co-author) (IF:2.7)
  7. Hsu FT*, Chen YT, Chin YC, Chang LC, Chiang SC, Yang LX, Liu HS, Yueh PF, Tu HL, He RY, Jeng LB, Shyu WC, Hu SH, Chiang IT, Liu YC, Chiu YC, Wu GC, Yu CC, Su WP*, Huang CC*. Harnessing the Power of Sugar-Based Nanoparticles: A Drug-Free Approach to Enhance Immune Checkpoint Inhibition Against Glioblastoma and Pancreatic Cancer. ACS Nano. 2024; 18 (42): 28764-28781. (Corresponding author) (IF: 15.8)
  8. Wang LC, Chang LC, Huang HL, Chang PY, Pao CW, Liu YF, Huang KS, Chien YH*, Sheu HS*, Su WP*, Yeh CH*, Yeh CS*. Synergistic ROS Generation via Core-Shell Nanostructures with increased lattice microstrain Combined with Single-Atom Catalysis for Enhanced Tumor Suppression. ACS Applied Materials & Interfaces. 2024; 16(34): 45356–45370. (Corresponding author) (IF: 8.5) 
  9. Wu CK (Su WP’s Ph.D. student), Shiu JL, Wu CL, Hung CF, Ho YC, Chen YT, Tung SY, Yeh CF, Shen CH, Liaw H*, Su WP*. APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance. Nucleic Acids Research. 2024; 52(10):5676-5697. (Corresponding author) (IF: 16.7) —成功大學醫學院年度論文
  10. Chang LC (Su WP’s Ph.D. student), Chin YC, Wu PC, Wei YF, Wu HC, Cheng TY, Liu YF, Huang CC*, Su WP*. Polymeric nano-formulation of spectrum selective RTK inhibitor strengthens anti-cancer effects via immune remodeling by endoplasmic reticulum stress-modulating mitochondrial metabolism. Nano Today. 2024 Feb; (54): 102070. (Corresponding author) (IF: 13.2) —2024年國家新創獎-學研新創
  11. Wang LC, Chiou PY, Hsu YP, Lee CL, Hung CH, Wu YH, Wang WJ, Hsieh GL, Chen YC, Chang LC, Su WP, et al. Prussian blue analog with separated active sites to catalyze water driven enhanced catalytic treatments. Nature Communications. 2023 Aug 5;14(1):4709. (IF: 16.6)
  12. Wang LC, Chang LC, Chen WQ, Chien YH, Chang PY, Pao CW, Liu YF, Hsu HS*, Yeh CH*, Su WP*, Yeh CS*. Atomically dispersed golds on degradable zero-valent copper nanocubes augment oxygen driven Fenton-like reaction for effective orthotopic tumor therapy. Nature Communications. 2022; 13: 7772. (Corresponding author) (IF: 17.694) 
  13. Wu CK, Wei MT, Wu HC, Wu CL, Wu CJ, Liaw H, Su WP*. BMP2 promotes lung adenocarcinoma metastasis through BMP receptor 2-mediated SMAD1/5 activation. Scientific Reports. 2022; 12: 16310 (Corresponding author) (IF: 4.997)
  14. Su WP*, Chang LC, Song WH, Yang LX, Wang LC, Chia ZC, Chin YC, Shan YS, Huang CC*, Yeh CS*. Polyaniline-Based Glyco-Condensation on Au Nanoparticles Enhances Immunotherapy in Lung Cancer. ACS Applied Materials & Interfaces. 2022; 14(21): 24144-24159. (First & Corresponding author) (IF: 10.383)
  15. Wang LC, Chang LC, Su GL, Chang PY, Hsu HF, Lee CL, Li JR, Liao MC, Sheu HS*, Tu TY*, Su CH*, Su WP*, Yeh CS*. Chemical structure and shape enhance MR imaging guided X-ray therapy following marginative delivery. ACS Applied Materials & Interfaces. 2022; 14(11): 13056-13069 (Corresponding author) (IF: 10.383) 
  16. Gupta T, Debele TA, Wei YF, Gupta A, Murtaza M, Su WP*. Synergistic action of Immunotherapy and Nanotherapy against cancer patients infected with SARS-CoV-2 and the use of Artificial Intelligence. Cancers. 2022; 14(1): 213. (Corresponding author) (IF: 6.575)
  17. S Bazarbashi, Su WP, SW Wong, RA Singarachari, S Rawal, MI Volkova, Da Bastos. A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries. Oncology and Therapy. 2021 Dec; 9(2):311-327. (IF: 3.2)
  18. Hsu LN#, Tsai YS#, Tsai HT, Su WP*, Tong YC*. Study on the pathophysiological mechanism responsible for lower urinary tract symptoms associated with prostate cancer using an animal model. LUTS. 2021 Jul; 13(3):390-399. (Corresponding author) (IF: 1.592)
  19. Manoharan D, Chang LC, Shan YS, Wang LC, Lin FC, Wu LC, Sheu HS, Su WP*, Yeh CS. Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-Ray Dose Delivery to Pancreatic Tumors. ACS Nano. 2021; 15 (5), 9084–9100. (Corresponding author) (IF: 15.881) 
  20. Debele TA, Wu PC, Wei YF, Chuang JY, Chang KY, Tsai JH, Su WP*. Transferrin Modified GSH Sensitive Hyaluronic Acid Derivative Micelle to Deliver HSP90 Inhibitors to Enhance the Therapeutic Efficacy of Brain Cancers. Cancers. 2021; 13 (10): 2375. (Corresponding author) (IF: 6.639)
  21. Pham KY, Wang LC, Hsieh CC, Hsu YP, Chang LC, Su WP, Chien YH, Yeh CS. 1550 nm excitation-responsive upconversion nanoparticles to establish dual-photodynamic therapy against pancreatic tumor. Journal of Materials Chemistry B., 2021 Jan; 9, 694-709. (SCI, 9/38, Materials Science,Biomaterials). (IF: 6.331)

Click Num:
Print
Login Success